MS Advanced Practice Providers

Recent analysis confirms cladribine's safety for multiple sclerosis, showing no increased pregnancy risks and effective long-term outcomes in patients.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting.

Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS.

Move fast—April 30, 2025, is the final day to take advantage of early bird savings!

Bruce Bebo, PhD, and Amit Bar-Or, MD, FRCPC, FAAN, FANA, discussed the impact of the John Dystel Prize on multiple sclerosis research and its role in shaping future clinical advancements.

In a large Swedish MS cohort, higher combined intake of lean and oily fish was linked to significantly reduced risks of confirmed disability worsening and EDSS progression, independent of lifestyle factors.

The director of NYU Langone's Multiple Sclerosis Comprehensive Care Center discussed the importance of early, high-efficacy treatment for pediatric MS. [WATCH TIME: 3 minutes]

Experts discussed recent advancements in diagnostic criteria, imaging techniques, and the evolving understanding of multiple sclerosis subtypes and treatment responses. [WATCH TIME: 10 minutes]

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania discussed evolving insights into the cellular immunology of multiple sclerosis. [WATCH TIME: 4 minutes]

The professor of neurology at University of Colorado School of Medicine talked about the challenges of telehealth and device-based data collection in clinical practice. [WATCH TIME: 4 minutes]

The professor of neurological sciences at the University of Vermont discussed the work of the MS Differential Diagnosis Consortium, highlighting efforts to refine MS differential diagnosis and improve clinical accuracy. [WATCH TIME: 8 minutes]

The medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed findings from phase 3 trials suggesting that baseline PRLs can predict disability accumulation and may serve as biomarkers for treatment response to tolebrutinib. [WATCH TIME: 6 minutes]

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

Explore the key 2024 neurology guideline updates shaping clinical care across stroke, epilepsy, movement disorders, and more in this essential feature.

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody-associated disease. [WATCH TIME: 3 minutes]

The professor of neurology and neurosurgery at McGill University discussed the evolving understanding of neuroimmune interactions in MS, highlighting how these interactions contribute to disease progression and potential repair mechanisms. [WATCH TIME: 4 minutes]

The professor of neurology at University of Colorado School of Medicine discussed the evolving landscape of MS treatment, highlighting the role of personalized medicine and biomarker-driven decision-making. [WATCH TIME: 5 minutes]

Neurology News Network. for the week ending March 8, 2025. [WATCH TIME: 3 minutes]

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital provided clinical insight on the complexities of treating pediatric MOGAD, including treatment options, decision-making factors, and emerging therapies. [WATCH TIME: 4 minutes]

At the 2025 ACTRIMS Forum, the director of the MS Comprehensive Care Center at Stony Brook Medicine discussed the evolution of high-efficacy treatments for MS. [WATCH TIME: 4 minutes]

At the 2025 ACTRIMS Forum, the system chief of neuroimmunology and multiple sclerosis at OhioHealth discussed the need for better tools to detect MS progression. [WATCH TIME: 3 minutes]

The assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed how the CALLIPER trial’s lower proportion of patients with gadolinium-enhancing lesions mirrors clinical practice more closely than other progressive MS trials. [WATCH TIME: 2 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed key insights into patient characteristics and lesion differences of the CALLIPER Trial in retrospect to other studies. [WATCH TIME: 4 minutes]

A significant number of pregnancies in NMOSD patients experienced relapses postpartum, with 50% of pregnancies showing complications for both mother and fetus.

Deborah Benzil, MD, FAAS, vice chair of neurosurgery at Cleveland Clinic's Center for Spine Health, shared her extraordinary journey of resilience, from overcoming repeated rejections to becoming a trailblazer for women in neurosurgery, and reflects on the progress made and the challenges that remain.

Explore some of the most highly anticipated clinical trials with data readouts expected in the second half of 2025—key updates that researchers and clinicians in neurology won’t want to miss.

The William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine talked about refining multiple sclerosis in line with the updated diagnostic criteria. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromyelitis optica spectrum disorder.

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]